- Company
- Early breast cancer treatments fail to get reimb in KOR
- by Eo, Yun-Ho Apr 8, 2024 05:46am
- It seems unlikely that a new reimbursed option will be introduced to the early breast cancer environment anytime soon. First, Lilly Korea again failed to overcome the barrier of the Health Insurance Review and Assessment Service's Cancer Disease Review Committee for its CDK4/6 inhibitor Verzenio (abemaciclib). This was the company’s seco
- Company
- Sanofi’s Dupixent sales skyrocket after expanded indication
- by Nho, Byung Chul Apr 8, 2024 05:46am
- Sanofi-aventis Korea’s Dupixent (dupilumab) has accomplished outstanding external growth in the market for asthma biologic treatments. Based on pharmaceutical drug sales performance, Dupixent generated sales of KRW 143.1 billion last year. It has been ranked as the top-selling drug for the past five years. Dupixent sales were aroun
- Company
- High dose Eylea approved in KOR… extends dosing interval
- by Son, Hyung-Min Apr 5, 2024 05:43am
- Bayer Korea announced that its Eylea 8mg, a treatment for macular degeneration, was approved in Korea on the 3rd. Eylea 8mg was developed to maintain the effective drug concentration in the eye longer than the already approved Eylea 2mg product, allowing for longer dosing intervals and fewer injections. Eylea is an intravitreal inject
- Company
- AbbVie Korea, 52% increase in sales last year…
- by Kim, Jin-Gu Apr 5, 2024 05:43am
- AbbVie Korea’s major performances, including sales and operating profit, have increased by about 50% in a year. The analysis attributes this to the integration with Korea’s Allergan. AbbVie headquarters initiated the integration process between both companies in June 2019. The analysis suggests that the company’s total assets have ex
- Company
- Boryung speeds up Lenvima patent challenge
- by Heo sung-kyu Apr 4, 2024 06:00am
- Boryung's challenge against Eisai’s blockbuster anticancer drug Lenvima is gathering pace. As the only domestic pharmaceutical company to continue the patent challenge, Boryung’s journey has passed the 70% mark. With only one patent remaining, expectations of the company’s launch of the Lenvima generic in 2025 are rising. According to i
- Company
- Enhertu lands in general hospitals in KOR after reimb
- by Eo, Yun-Ho Apr 4, 2024 06:00am
- Hospitals in Korea are busy preparing a prescription environment for the reimbursed Enhertu. According to industry sources, Daiichi Sankyo and AstraZeneca Korea’s antibody-drug conjugate (ADC) for HER2-positive breast cancer, Enhertu (trastuzumab deruxtecan) has passed the drug committee (DC) review of 46 medical institutions in Korea,
- Company
- AbTis-Progen signs MOU to develop bispecific antibody ADC
- by Son, Hyung-Min Apr 3, 2024 05:51am
- AbTis, Dong-A ST’s affiliate specializing in ADC, announced on April 1 that it has signed a memorandum of understanding (MOU) with Progen to develop a bispecific antibody-drug conjugate (BsADC) to treat autoimmune diseases. The MOU will leverage the two companies’ proprietary platform technologies - AbTis’ AbClick and Progen's NTIG.
- Company
- Hanmi files phase 1 FDA IND for their next-gen obesity drug
- by Son, Hyung-Min Apr 3, 2024 05:50am
- Hanmi Pharmaceutical announced on the 1st that it submitted an investigational new drug (IND) to the U.S. FDA on March 29 for its triple-agonist (HM15275), a next-generation obesity drug. Its IND includes a trial goal to assess drug tolerance, pharmacokinetics, and pharmacodynamics of HM15275 in healthy adults and patients with obesity.
- Company
- Pharmas face sales challenges and rebate monitoring
- by Son, Hyung-Min Apr 3, 2024 05:50am
- As the ongoing feud between the medical community and the government over the medical school quota continues, the pharmaceutical industry faces the full impact. In addition to major hospitals, outpatient clinics have shortened working hours, making it difficult for some pharmaceutical company employees even to meet medical professionals. Sales a
- Company
- Pfizer expands co-marketing partnership deals
- by Son, Hyung-Min Apr 3, 2024 05:50am
- Pfizer Korea will co-market 2 blockbuster autoimmune disease drugs with a local drug distributor Hanlim MS. Pfizer has signed copromotion deals with Jeil Pharmaceutical, Donghwa Pharm, and Chong Ku Dang, but this is the first time the company has signed a co-marketing partnership deal with Hanlim MS. The company explained that it decided to part
